July 9 (Reuters) - Helix Biopharma Corp HBP.TO :
* HELIX BIOPHARMA CORP. SUBMITS L-DOS47 IND APPLICATION WITH U.S. FDA FOR PANCREATIC CANCER
* HELIX BIOPHARMA - SUBMISSION OF IND WITH U.S. FDA FOR APPROVAL TO INITIATE PHASE I/II CLINICAL STUDY PROTOCOL WITH L-DOS47 WITH DOXORUBICIN